{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=19&state=California",
    "query": {
      "state": "California",
      "city": "Sacramento",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 5549,
    "total_pages": 555,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=20&state=California&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=18&state=California&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T13:53:26.772Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00325403",
      "title": "FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Oral treprostinil (UT-15C) Sustained Release Tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 349,
      "start_date": "2006-10",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2024-01-03",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00325403"
    },
    {
      "nct_id": "NCT03441555",
      "title": "A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Alvocidib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2018-05-30",
      "completion_date": "2021-01-25",
      "has_results": false,
      "last_update_posted_date": "2022-02-01",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03441555"
    },
    {
      "nct_id": "NCT01026220",
      "title": "Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma",
        "Stage III Childhood Hodgkin Lymphoma",
        "Stage IV Childhood Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "bleomycin sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "liposomal vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine tartrate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide phosphate",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 166,
      "start_date": "2009-12-07",
      "completion_date": "2022-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 156,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 121 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01026220"
    },
    {
      "nct_id": "NCT03902080",
      "title": "Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Vibegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "45 Years and older · Male only"
      },
      "enrollment_count": 1105,
      "start_date": "2019-03-26",
      "completion_date": "2023-06-15",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 75,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03902080"
    },
    {
      "nct_id": "NCT02169362",
      "title": "Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Deep Partial Thickness Thermal Burns"
      ],
      "interventions": [
        {
          "name": "Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Arteriocyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "86 Years",
        "sex": "ALL",
        "summary": "18 Years to 86 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-07",
      "completion_date": "2018-05",
      "has_results": false,
      "last_update_posted_date": "2017-04-13",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02169362"
    },
    {
      "nct_id": "NCT02187159",
      "title": "Treatment of Pain Associated With Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain Associated With Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "DS-5565",
          "type": "DRUG"
        },
        {
          "name": "Pregabalin",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1270,
      "start_date": "2014-11",
      "completion_date": "2016-07-07",
      "has_results": true,
      "last_update_posted_date": "2020-11-09",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 86,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 81 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02187159"
    },
    {
      "nct_id": "NCT04320888",
      "title": "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphatic System Neoplasm",
        "Recurrent Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Hepatoblastoma",
        "Recurrent Histiocytic and Dendritic Cell Neoplasm",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Lymphoma",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Glioma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Recurrent WHO Grade 2 Glioma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma",
        "Refractory Hepatoblastoma",
        "Refractory Histiocytic and Dendritic Cell Neoplasm",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Lymphoma",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Glioma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Refractory WHO Grade 2 Glioma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 1,
      "start_date": "2021-05-03",
      "completion_date": "2027-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 172,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04320888"
    },
    {
      "nct_id": "NCT00583973",
      "title": "Effect of Parenteral Iron Therapy on Inflammatory Response and Oxidative Stress Chronic Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemodialysis",
        "Chronic Kidney Disease",
        "Inflammation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2007-01",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2017-06-21",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00583973"
    },
    {
      "nct_id": "NCT02046941",
      "title": "Brain Biomarkers of Response to Treatment for Apraxia of Speech",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aphasia",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Speech Production Treatment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 17,
      "start_date": "2014-03-01",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02046941"
    },
    {
      "nct_id": "NCT04437173",
      "title": "Pain Procedures and Anxiolysis Via Distraction With Virtual Reality",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Virtual Reality",
        "Anxiety",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Virtual Reality Headset Distraction",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2020-08-07",
      "completion_date": "2022-02-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-10-29T13:53:26.772Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04437173"
    }
  ]
}